Key Drivers
- Net cash
- High margins
- Tax benefit
AIAI Summary
AUPH now looks less like a speculative biotech and more like a profitable LUPKYNIS-driven cash generator, but the investable question is whether management can keep growing and defend exclusivity before competitive or patent pressure erodes the franchise, making execution on commercial momentum and franchise protection the key takeaway.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Net cash
- •High margins
- •Tax benefit
AUPH has a strong net cash position, high margins, and efficient cash generation, but its valuation already reflects quality and reported net income was boosted by a one-time tax benefit.
Price Behavior
Key Price Behavior Insights:
- •Support holding
- •Resistance overhead
- •Breakout needed
AUPH has been slightly weaker over the last month, but repeated support near $15.18-$15.19 keeps the setup constructive, while a move above $16.13 would improve the outlook and a break below $15.18 would raise risk of a retest of $14.57.
Sharp rebound from $14.57 to $16.13 shows buyers stepped in after weakness
Sentiment & News
Key News Insights:
- •Earnings Beat
- •Pipeline Progress
- •Exclusivity Risk
Aurinia beat quarterly EPS expectations and highlighted ongoing Lupkynis/pipeline progress, but exclusivity risk remains an important overhang.
The strong earnings print is a near-term positive, but the stock's upside may stay capped until the company clears key pipeline and market-exclusivity uncertainties
Similar Companies in Healthcare
Other companies in the same sector with AI ratings